Cost-effectiveness of 3-year vs 1-year adjuvant therapy with imatinib in patients with high risk of gastrointestinal stromal tumour recurrence in the Netherlands; a modelling study alongside the SSGXVIII/AIO trial

References

• van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer 2005;104:1781-8
   PubMedGoogle Scholar
• Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumors: radiologic features with pathologic correlation. Radiographics 2003;23:283-304, 456; quiz 532
   PubMedGoogle Scholar
• Pidhorecky I, Cheney RT, Kraybill WG, et al. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 2000;7:705-12
   PubMed Web of Science ®Google Scholar
• Mucciarini C, Rossi G, Bertolini F, et al. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer 2007;7:230
   Google Scholar
• Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era–a population-based study in western Sweden. Cancer 2005;103:821-9
   PubMed Web of Science ®Google Scholar
• Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide study. Eur J Cancer 2005;41:2868-72
   PubMed Web of Science ®Google Scholar
• Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002;3:655-64
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9
   PubMed Web of Science ®Google Scholar
• Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-80
   PubMed Web of Science ®Google Scholar
• Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-38
   PubMed Web of Science ®Google Scholar
• Miettinen M, Virolainen M, Sarlomo-Rikala M. Gastrointestinal stromal tumors–value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol 1995;19:207-16
   PubMed Web of Science ®Google Scholar
• Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol 1998;11:728-34
   PubMed Web of Science ®Google Scholar
• Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003;299:708-10
   PubMed Web of Science ®Google Scholar
• Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83
   PubMed Web of Science ®Google Scholar
• Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet 2007;369:1731-41
   PubMed Web of Science ®Google Scholar
• Demetri GD, von Mehren M, Antonescu CR, et al. NCCN Task Force Report: Update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Cancer Netw 2010;8(2 Suppl):S-1–S-41
   Google Scholar
• Casali PG, Blay JY, Esmo Conticanet Eurobonet Consensus Panel of Experts. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(5 Suppl):98-102
   Google Scholar
• Rutkowski P, Bylina E, Wozniak A, et al. Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour - the impact of tumour rupture on patient outcomes. Eur J Surg Oncol 2011;37:890-6
   PubMed Web of Science ®Google Scholar
• Reid R, Bulusu R, Carroll N, et al. Guidelines for the Management of Gastrointestinal Stromal Tumours (GIST). Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, 2009
   Google Scholar
• Integraal Kankercentrum Nederland, Wekedelentumoren. Landelijke richtlijn, Versie 2.0, Leiden, Netherlands, 2011
   Google Scholar
• Edmonson JH, Marks RS, Buckner JC, et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002;20:605-12
   PubMed Web of Science ®Google Scholar
• Dematteo RP, Heinrich MC, El-Rifai WM, et al. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002;33:466-77
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals UK Ltd. Summary of Product Characteristics last updated on the eMC: 06/03/2012. London, UK: European Medicines Agency; 2012. http://www.medicines.org.uk/EMC/medicine/15014/SPC/GLIVEC+Tablets/#CATEGORY. Accessed September 25, 2012
   Google Scholar
• Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373:1097-104
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Data on file - ACOSOGZ9001 Tables and Listings for High Risk Patients. London, UK: Novartis Pharmaceuticals; 2010
   Google Scholar
• Scottish Medicine Consortium. Advice following submission of new product assessment form for imatinib in GIST. Glasgow: SMC, 2010
   Google Scholar
• Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307:1265-72
   PubMed Web of Science ®Google Scholar
• Jiang WZ, Guan GX, Lu HS, et al. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months. J Surg Oncol 2011;104:760-4
   Google Scholar
• Li J, Gong JF, Wu AW, et al. Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor. Eur J Surg Oncol 2011;37:319-24
   PubMed Web of Science ®Google Scholar
• , B. I. G. Collaborative GroupMouridsen H, Giobbie-Hurder A, et al. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med 2009;361:766-76
   Google Scholar
• , Group Breast International Group 1–98 CollaborativeThurlimann B, Keshaviah A, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57
   Google Scholar
• National Institute for Health and Clinical Excellence. Melanoma (stage III or IV) – ipilimumab: appraisal consultation document. Guidance in development, Appraisals. London, UK: NICE, National Institute for Health and Clinical Excellence; 2012
   Google Scholar
• Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices–Modeling Studies. Value Health 2003;6:9-17
   PubMed Web of Science ®Google Scholar
• Ramsey S, Willke R, Briggs A, et al. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005;8:521-33
   PubMed Web of Science ®Google Scholar
• CvZ. Guidelines for pharmacoeconomic research, updated version. Diemen, The Netherlands: College voor Zorgverzekeringen, 2006
   Google Scholar
• Renshaw AE, Haberman S. On the forecasting of mortality reduction factors. Insurance: Mathematics and Economics 2003;32:379-401
   Web of Science ®Google Scholar
• Reichardt P, Blay JY, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23:1680-7
   PubMed Web of Science ®Google Scholar
• Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-34
   PubMed Web of Science ®Google Scholar
• CBS. StatLine. Centraal Bureau voor de Statistiek, 2012
   Google Scholar
• Heintz D, Noronha-Jackson A, Green S. Short (12 months) versus long (36 months) duration of adjuvant treatment with the tyrosine kinase inhibitor imatinib mesylate of perable GIST with a high risk for recurrence: a randomised Phase III study. Clinical Study Report STI571BF103. (Data on file, commercial in confidence). Novartis, London, UK: Novartis Pharmaceuticals; 2011
   Google Scholar
• Chabot I, LeLorier J, Blackstein ME. The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: The example of sunitinib for gastrointestinal stromal tumour. Eur J Cancer 2008;44:972-7
   PubMed Web of Science ®Google Scholar
• Ara R, Brazier JE. Populating an economic model with health state utility values: moving toward better practice. Value Health 2010;13:509-18
   PubMed Web of Science ®Google Scholar
• College voor Zorgverzekeringen. Medicijnkosten. Diemen: College voor Zorgverzekeringen, 2012
   Google Scholar
• Polder JJ, Barendregt JJ, van Oers H. Health care costs in the last year of life–the Dutch experience. Soc Sci Med 2006;63:1720-31
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, García del Muro X, Grande E, et al. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clin Transl Oncol 2008;10:831-9
   PubMed Web of Science ®Google Scholar
• Sanon M, Taylor DC, Parthan A, et al. Cost-effectiveness of 3-years of adjuvant imatinib in gastrointestinal stromal tumors (GIST) in the United States. J Med Econ 2012;15:1-10
   Google Scholar
• Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68
   PubMed Web of Science ®Google Scholar
• Italiano A, Cioffi A, Coco P, et al. Patterns of care, prognosis, and survival in patients with Metastatic Gastrointestinal Stromal Tumors (GIST) refractory to first-line imatinib and second-line sunitinib. Ann Surg Oncol 2012;19:1551-9
   PubMed Web of Science ®Google Scholar
• Reichardt P, Blay J-Y, Gelderblom H, et al. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib. Ann Oncol 2012;23:1680-7
   PubMed Web of Science ®Google Scholar
• Demetri GD, Reichardt P, Kang DY, et al. Randomized phase III trial of regorafenib in patients (pts) with metastatic and/or unresectable gastrointestinal stromal tumor (GIST) progressing despite prior treatment with at least imatinib (IM) and sunitinib (SU): GRID trial, in American Society of Clinical Oncology 2012, J Clin Oncol: Chicago, IL
   Google Scholar
• Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-9
   PubMed Web of Science ®Google Scholar
• Hakkaart- van Roijen L, Tan SS, Bouwmans CAM. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2010. Diemen: College voor Zorgverzekeringen, 2010;42
   Google Scholar